Autoantibodies: Pathogenic or epiphenomenon

Elsevier

Available online 7 July 2022, 101767

Best Practice & Research Clinical RheumatologyAbstract

Idiopathic inflammatory myopathies (IIM) are heterogeneous autoimmune diseases. There are distinct subgroups, including antisynthetase syndrome, dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and sporadic inclusion body myositis. In patients with IIM, autoantibodies are present in up to 80% of the patients. These autoantibodies are often characterized as myositis-specific autoantibodies (MSA) or myositis-associated autoantibodies (MAA). The recognition of the importance of autoantibodies, especially MSA, is increasing in recent years. In this chapter, we provide an overview of the MSAs, including some new autoantibodies of interest as they target mainly muscle-specific autoantigen, in clinical classification, the measurement of the disease activity, and a possible role in the pathogenesis in the patients with IIM.

Keywords

Myositis

Autoantibodies

Autoantigens

Pathogenesis

© 2022 The Author(s). Published by Elsevier Ltd.

留言 (0)

沒有登入
gif